1900. Association of Spontaneous Abortion and Receipt of Inactivated Influenza Vaccine Containing H1N1pdm09 in Early Pregnancy
Session: Poster Abstract Session: Vaccines: Influenza
Saturday, October 10, 2015
Room: Poster Hall
Posters
  • IDSA_2015 poster-6.pdf (160.5 kB)
  • Background: Most studies report that inactivated influenza vaccination (IIV) during pregnancy is safe, but evidence of safety in early pregnancy is limited, including for newer vaccines that contain A/H1N1pdm2009 (pH1N1) antigen.  We conducted a matched case-control study in the Vaccine Safety Datalink (VSD) to determine if IIV was associated with spontaneous abortion (SAB) during the 2010-11 and 2011-12 influenza seasons, two years in which the vaccine composition was unchanged.

    Methods: Cases (women with SAB) and controls (women with live births or stillbirths) were identified using administrative, clinical, and claims data; medical records were abstracted to confirm pregnancy, vaccinations, and estimate the SAB date.  Cases and controls were matched on VSD site, last menstrual period, and age (<30, ≥30 years).  The primary exposure was IIV in the 1-28 days before SAB; two other risk windows (29-56 and >56 days) were also evaluated.  The analysis adjusted for age and other potential confounders.  A post-hoc analysis assessed whether vaccination in the prior season modified the association between IIV and SAB.

    Results: The analysis included 485 matched pairs.  The adjusted odds ratio (aOR) was 2.0 (95% CI 1.1-3.6) for IIV in the 1-28 days before SAB compared to unvaccinated women; there was no association in the other risk windows.  In season-specific analyses, the aOR in the 1‑28 days was 3.7 (95% CI 1.4-9.4) in 2010-11 and 1.4 (95% CI 0.6-3.3) in 2011-12.  Among all women who received pH1N1-containing vaccine in the influenza season prior to study entry, the aOR in the 1-28 days was 7.7 (95% CI 2.2-27.3); the aOR was 1.3 (95% CI 0.7-2.7) among women not vaccinated in the prior season (P=0.02 for effect modification).  This effect modification due to prior season vaccination was observed in each season.  There was no association in the other risk windows regardless of past exposure to pH1N1-containing vaccine.

    Conclusion: In the primary analysis that included two influenza seasons, SAB was associated with IIV in the 1‑28 days before SAB; the elevated risk was confined to women who also received pH1N1-containing vaccine in the prior season.  The overall association between IIV and SAB in the 1-28 days was significant in 2010-11, but not in 2011‑12.  However, the elevated risk among women previously vaccinated with pH1N1-containing vaccine was observed in each season.

    James Donahue, DVM, PhD1, Burney Kieke, MS1, Jennifer King, MPH1, Frank Destefano, MD, MPH2, Maria Mascola, MD, MPH3, Stephanie Irving, MHS4, Craig Cheetham, PharmD5, Jason Glanz, PhD6, Lisa A. Jackson, MD, MPH, FIDSA7, Nicola P. Klein, MD, PhD8, Allison Naleway, PhD9, Eric Weintraub, MPH10, Edward Belongia, MD1 and the Vaccine Safety Datalink, (1)Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Foundation, Marshfield, WI, (2)Centers for Disease Control and Prevention, Atlanta, GA, (3)Department of OB-GYN, Marshfield Clinic, Marshfield, WI, (4)The Center for Health Research, Kaiser Permanente Northwest, Portland, OR, (5)Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, (6)Kaiser Permanente Colorado, Denver, CO, (7)Center for Health Studies, Seattle, WA, (8)Kaiser Permanente Vaccine Study Center, Oakland, CA, (9)Kaiser Permanente Center for Health Research, Portland, OR, (10)Immunization Safety Office, Centers for Disease Control and Prevention, Atlanta, GA

    Disclosures:

    J. Donahue, None

    B. Kieke, MedImmune: Investigator , Research support

    J. King, None

    F. Destefano, None

    M. Mascola, None

    S. Irving, None

    C. Cheetham, None

    J. Glanz, None

    L. A. Jackson, None

    N. P. Klein, GSK: Grant Investigator , Research grant
    Sanofi Pasteur: Grant Investigator , Research grant
    Pfizer: Grant Investigator , Research grant
    Merck: Grant Investigator , Research grant
    Novartis: Grant Investigator , Research grant
    Nuron Biotech: Grant Investigator , Research grant
    Protein Science: Grant Investigator , Research grant and Research support
    MedImmune: Grant Investigator , Research grant

    A. Naleway, GlaxoSmithKline: Investigator , Research support

    E. Weintraub, None

    E. Belongia, Medimmune: Investigator , Research support

    See more of: Vaccines: Influenza
    See more of: Poster Abstract Session

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.